C
CHARM Therapeutics
Uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins
About CHARM Therapeutics
A 3D deep-learning research company that discovers and develops medicines for diseases such as cancer.
Read full description
CHARM Therapeutics utilizes its proprietary DragonFold platform, which is based on protein-ligand co-folding, to identify novel molecules for drug discovery. The company has a strategic focus on creating small-molecule drugs. The business model appears to be centered on leveraging its advanced AI-driven technology to accelerate the drug discovery process, potentially entering into collaborations and partnerships with larger pharmaceutical companies, as evidenced by their collaboration with Bristol Myers Squibb. The company has raised a total of $70 million in funding to date, which supports its research and development activities. The primary clients and beneficiaries of CHARM's work would be patients in need of new treatments, and their partners in the pharmaceutical industry.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 63.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, uk rio, Drug Development, Core AI, UKis Digital and technologies, Tech for Biotech and Pharma, uk is8 digital and technologies, uk is8 life sciences, comp bio and chem, AI Drug Discovery, BIA Techbio UK
- Business model
- SaaS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $80M | $320M | Nvidia · Khosla Ventures · OrbiMed · NEA | ↗ |
| EARLY VCOther financing | Apr 2023 | $20M | $80M | NVentures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for CHARM Therapeutics is 6.1K monthly website visits, up 13% over the last three months. CHARM Therapeutics's team declined 10.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
OrbiMed
F-Prime
General Catalyst
Khosla Ventures
Bravos Capital
Axial VC
NVentures
NEA
SR One
Nvidia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CHARM Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CHARM Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.